Skip to main content

Market Overview

Alnylam's Oxalate-Lowering Therapy Shows Significant Clinical Benefit; Data Published In New England Journal Of Medicine

Alnylam's Oxalate-Lowering Therapy Shows Significant Clinical Benefit; Data Published In New England Journal Of Medicine
  • Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) has announced that trial results from the ILLUMINATE-A Phase 3 study evaluating lumasiran for the treatment of primary hyperoxaluria type 1 (PH1). The results were published online in The New England Journal of Medicine.
  • Lumasiran an RNAi therapeutic targeting hydroxyacid oxidase 1 (HAO1) – the gene encoding glycolate oxidase (GO)
  • In November last year, Oxlumo (lumasiran) was approved by the FDA to treat PH1 in pediatric and adult patients and received marketing authorization from the European Commission for the treatment of PH1 in all age groups.
  • The data reported in the publication demonstrated that lumasiran led to substantial and sustained reductions in urinary oxalate, the toxic metabolite responsible for the clinical manifestations of PH1.
  • As compared to placebo, treatment with lumasiran resulted in a clinically significant (53.5%) reduction in 24-hour urinary oxalate excretion from baseline to month 6.
  • Improvements were also observed in many secondary endpoints, including the proportion of patients achieving normal or near-normal urinary oxalate levels, with 84% of lumasiran-treated patients compared with no patients on placebo.
  • Patients treated with lumasiran also experienced favorable effects on exploratory endpoints related to nephrocalcinosis and the rate of renal stone events compared with placebo.
  • Lumasiran was associated with a favorable safety and tolerability profile, with no serious or severe adverse events.
  • Price Action: ALNY shares are trading 0.96% higher at $142.55 in the premarket session on the last check Thursday.

Related Articles (ALNY)

View Comments and Join the Discussion!

Posted-In: Primary HyperoxaluriaBiotech News Health Care General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at